Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
POAI 
Predictive Oncology Inc (POAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: POAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.02% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.41M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.2 | 52 Weeks Range 0.55 - 2.25 | Updated Date 07/1/2025 |
52 Weeks Range 0.55 - 2.25 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2073.29% |
Management Effectiveness
Return on Assets (TTM) -73.2% | Return on Equity (TTM) -490.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6244733 | Price to Sales(TTM) 4.29 |
Enterprise Value 6244733 | Price to Sales(TTM) 4.29 | ||
Enterprise Value to Revenue 3.61 | Enterprise Value to EBITDA -0.51 | Shares Outstanding 8931620 | Shares Floating 8818457 |
Shares Outstanding 8931620 | Shares Floating 8818457 | ||
Percent Insiders 1.27 | Percent Institutions 2.07 |
Analyst Ratings
Rating 1 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Predictive Oncology Inc
Company Overview
History and Background
Predictive Oncology Inc. was founded to leverage artificial intelligence and machine learning to improve cancer treatment development. Originally focused on drug discovery, they've evolved to offer predictive testing services and solutions.
Core Business Areas
- Drug Discovery and Development: Utilizes AI and machine learning to identify promising drug candidates and accelerate the drug development process.
- Patient-Specific Cancer Modeling: Develops models of individual patients' cancers to predict treatment response and guide personalized medicine decisions.
- Research Services: Offer various contract research services for cancer therapies
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and pharmaceutical industries. The company structure includes departments for R&D, business development, and operations.
Top Products and Market Share
Key Offerings
- PEDAL Platform: AI-powered platform used to predict drug response. Market share for AI-driven drug discovery is still emerging. Competitors include Recursion Pharmaceuticals (RXRX).
- ChemoFx: Proprietary laboratory test to predict a patient's tumor response. Market share is difficult to assess but has increased in recent years. Competitors include Exact Sciences (EXAS).
- TumorGenesis: 3D cell culture and analysis system for drug discovery, personalized medicine. Market share is difficult to assess. Competitors include Corning (GLW).
Market Dynamics
Industry Overview
The industry is driven by the need for more effective and personalized cancer treatments. Significant growth is expected in the AI-driven drug discovery and diagnostics sectors.
Positioning
Predictive Oncology Inc. positions itself as a leader in AI-driven oncology solutions, offering services to pharmaceutical companies and researchers. Competitive advantages include their proprietary AI platform and clinical data.
Total Addressable Market (TAM)
The total addressable market for AI in drug discovery and personalized medicine is estimated to be in the billions of dollars. Predictive Oncology is positioned to capture a significant share of this market with its technology.
Upturn SWOT Analysis
Strengths
- Proprietary AI platform
- Expertise in oncology and drug discovery
- Clinical data assets
- Strong research partnerships
Weaknesses
- Limited financial resources
- Reliance on partnerships and collaborations
- Smaller market capitalization compared to major competitors
- Limited commercial traction
Opportunities
- Growing demand for personalized cancer treatments
- Increasing adoption of AI in drug discovery
- Potential for strategic partnerships with pharmaceutical companies
- Expanding into new markets and applications
Threats
- Competition from larger, better-funded companies
- Regulatory hurdles
- Technological advancements that could render their platform obsolete
- Economic downturns that could impact R&D spending
Competitors and Market Share
Key Competitors
- RXRX
- EXAS
- MRNA
Competitive Landscape
POAI is small compared to competitors, and focuses on smaller specialized applications of AI for oncology.
Major Acquisitions
Quantitative Medicine
- Year: 2020
- Acquisition Price (USD millions): 2.1
- Strategic Rationale: Expanded POAI's capabilities in AI-driven drug development and personalized medicine.
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent, driven by deals, acquisitions, and new technology launches.
Future Projections: Analyst estimates vary, but project continued growth in revenue and market share as AI adoption in drug discovery increases.
Recent Initiatives: Focus on expanding commercial partnerships and developing new AI-powered solutions.
Summary
Predictive Oncology has the potential to be a key player in cancer diagnostics and drug discovery. They have strengths in their core technology but also weaknesses around financial strength. They have a good potential for growth but are also exposed to numerous threats. Their overall success relies on their strategy execution and obtaining new capital to fund growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases, SEC filings, Analyst reports, Market research reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Predictive Oncology Inc
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2018-01-29 | CEO & Chairman Mr. Raymond F. Vennare | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 23 | Website https://predictive-oncology.com |
Full time employees 23 | Website https://predictive-oncology.com | ||
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.